Business Wire

Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Share

Knopp Biosciences LLC today reported further clinical and biomarker data demonstrating that reduction in eosinophil count by oral dexpramipexole significantly correlated with improved lung function in the positive Phase 2 EXHALE trial of dexpramipexole in patients with moderate-to-severe eosinophilic asthma. The data were presented in a late-breaking abstract session at the European Respiratory Society International Congress 2021.

Eosinophils, a type of white-blood cell, are validated as a therapeutic target in asthma by the regulatory approval of multiple eosinophil-lowering biologics. Treatments approved to date for eosinophilic asthma are monoclonal antibodies requiring injection or infusion; dexpramipexole is administered orally.

The EXHALE trial was a randomized, double-blind, placebo-controlled trial of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) ≥300/µL. Dexpramipexole study drug at oral doses of 75 mg/day, 150 mg/day, or 300 mg/day was added to standard of care. The primary endpoint was change in AEC from Baseline to Week 12 compared to placebo.

As previously reported, EXHALE met its primary endpoint, demonstrating dose-dependent lowering of eosinophils, with significant reductions in AEC from Baseline to Week 12 at all doses tested (75 mg/day: ratio to Baseline 0.40, p=0.019; 150 mg/day: ratio to Baseline 0.31, p=0.001, and 300 mg/day: ratio to Baseline 0.21, p<0.0001). Dexpramipexole demonstrated a significant, dose-dependent effect on eosinophil lowering by log-linear testing (p<0.001), and a significant increase from baseline in lung function as measured by prebronchodilator FEV1 change (ΔFEV1 +172 mL vs placebo, p=0.015), pooling data across study arms (75 mg/day, 150 mg/day, and 300 mg/day) and visits (Weeks 4, 8, 12, and 16/18).

Today’s presentation to ERS 2021 reported that eosinophil reduction by dexpramipexole significantly correlated with improvement in prebronchodilator FEV1 (combined 300 mg/day and 150 mg/day dexpramipexole, Spearman correlation coefficient -0.58, p<0.0001). FEV1, the amount of air a patient can forcibly exhale in one second, is a fundamental measure of asthma control.

The newly reported results also included the dose-dependent effects of dexpramipexole on nasal eosinophil peroxidase (EPX), a marker of airway eosinophilia associated with mucus plugging and airway trapping in severe asthma.1 In a prespecified analysis, nasal EPX at Week 12 was reduced by 89.0% (p=0.020), 82.6% (p=0.021), 35.5% (p=0.540), and 16.7% for the 300 mg/day, 150 mg/day, 75 mg/day, and placebo arms, respectively (p-values relative to placebo). These results reinforced previous reports showing effective tissue eosinophil lowering by dexpramipexole in chronic rhinosinusitis with nasal polyps and hypereosinophilic syndrome.2,3

“These results add to the body of evidence that dexpramipexole reduces eosinophil burden in affected tissues as well as in blood, and strengthen the hypothesis that reductions in blood and tissue eosinophils by dexpramipexole is associated with improved lung health,” said Michael Bozik, M.D., CEO of Knopp. “As we prepare for entry into Phase 3 clinical trials, the results also reinforce our confidence in the potential of dexpramipexole as the first oral agent that can significantly reduce the risk of exacerbations in eosinophilic asthma.”

As previously reported, dexpramipexole was well tolerated in the EXHALE trial, with no serious adverse events and no adverse events leading to discontinuation. Seventy-four of the 76 dexpramipexole-treated patients completed the primary assessment phase.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in development for moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and smooth-muscle disorders. Please visit www.knoppbio.com.

ABOUT DEXPRAMIPEXOLE

Dexpramipexole, a selective inhibitor of eosinophil maturation, is an oral small molecule drug in development by Knopp for asthma and other eosinophil-associated diseases. In hypereosinophilic syndrome, dexpramipexole has previously been shown in a Phase 2 trial to significantly reduce requirements for oral corticosteroids and in a subset of patients to produce durable disease remission. In its earlier development in amyotrophic lateral sclerosis, dexpramipexole was shown to be well tolerated in Phase 1, Phase 2, and Phase 3 trials comprising approximately 1,200 patients.

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events, or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing pre-clinical or clinical study to verify their safety and effectiveness.


1 Dunican EM et al. J Clin Invest. 2018 Mar 1; 128(3): 997–1009.

2Laidlaw TM et al. Laryngoscope. 2019 Feb;129(2):E61-E66.

3Panch SR et al. Blood. 2018 Aug 2; 132(5): 501–509.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tom Petzinger
tom@knoppbio.com
+1-412-488-1776

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ISAE SUPAERO Opens Its Campus on Saturday 9 October 2021 from 10am to 6pm21.9.2021 10:49:00 CEST | Press release

As part of the Fête de la Science, which this year will have the theme "The thrill of discovery", ISAE-SUPAERO will once again open its entire campus to the public on Saturday 9 October from 10am to 6pm. In the respect of the sanitary rules and on delivery of the sanitary pass, this event for families, companies, partners, journalists or alumni, plans to gather, 3000 people! For the first time, ISAE-SUPAERO offers the possibility to visit the campus in the form of thematic tours: orientation tour, aeronautics tour, space tour, sustainable development tour, family tour and ISAE-SUPAERO in brief. At the same time, the conferences will be broadcast live on the Institute's website so that as many people as possible can attend. The programme includes - Visits to laboratories and research departments - Visit of the aero-acoustic wind tunnel - Demonstrations of ISAE SUPAERO infrastructures - Meetings with the student clubs - Exhibition: 1961-2021 Toulouse, a successful aerospace decentralisat

Dyne.org, RIDDLE&CODE and InfoCert's Consortium Appointed to Take EBSI to the Next Level21.9.2021 10:05:00 CEST | Press release

The consortium formed by Dyne.org, RIDDLE&CODE and InfoCert, has been selected by the European Commission as one of seven contractors to develop the next version of the European Blockchain Services Infrastructure (EBSI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005128/en/ The award is one more milestone in the consortium's track record of excellence with cryptography and blockchain, after Dyne.org led the flagship H2020 project DECODE, RIDDLE&CODE's blockchain solutions are deployed in banking and utility markets Europe wide and InfoCert being the largest Certification Authority at European level and eIDAS certified QTSP. The European Commission's vision for EBSI is to leverage distributed ledger technologies to create international and intra-communautaire services for public administrations. The European Blockchain Partnership aims to scale the investment fund to a fully developed platform with up to €2 billion

Velodyne Lidar Announces Multi-Year Supply Agreement with TOPODRONE21.9.2021 10:00:00 CEST | Press release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a multi-year agreement to provide its lidar sensors to TOPODRONE, which is based in Switzerland and develops affordable, high-precision solutions for aerial surveys. Using Velodyne lidar sensors has enabled TOPODRONE to bring high-precision mapping and 3D modeling to demanding environments including farms, forests, infrastructure and more to support development that advances economic and sustainability goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005316/en/ Velodyne Lidar announced a multi-year agreement to provide its lidar sensors to TOPODRONE, which is based in Switzerland and develops affordable, high-precision solutions for aerial surveys. Using Velodyne lidar sensors has enabled TOPODRONE to bring high-precision mapping and 3D modeling to demanding environments including farms, forests, infrastructure and more. (Photo: TOPODRONE) Velodyne (Hall:

CSC Adds Two Industry Leaders in Luxembourg; Secures Fund Administration and Depositary Licenses for Additional Services21.9.2021 10:00:00 CEST | Press release

CSC, the world’s leading provider of business, legal, tax, and digital brand services, has significantly expanded its operations in Luxembourg by securing new fund administration and depositary licenses and adding two experienced executives to help lead its growth in the market. This further extends CSC’s European fund administration and depositary offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005284/en/ Yves Cheret (Photo: Business Wire) With these key hires, clients will benefit from the addition of more than 30 years of combined industry expertise to CSC’s long-standing service offerings, including a range of alternative investment, capital markets, and corporate solutions. In addition, these new licenses will open new and essential services to clients in Luxembourg, yet another key European financial center in CSC’s growing footprint. Veteran talent, local expertise Pierre Mifsud joins as managing direc

Square Launches Integrated, Omnichannel Solutions For Businesses in France21.9.2021 09:00:00 CEST | Press release

Today Square, the globally trusted software, payments, and hardware solution for businesses of all sizes, launches in France. Following a successful Early Access Programme, now small businesses and large enterprises across France can access Square’s innovative ecosystem with the tools they need to start, run, grow, and adapt their businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005137/en/ Square Launches Integrated, Omnichannel Solutions For Businesses in France (Photo: Business Wire) “I’ve been using Square’s products both on-site and online over the past few months and it has revolutionised how I run my business,” said Anne-Laure Fonrose, Founder of Tatie Nanna. “Having an integrated, omnichannel payment solution means our customers can pay in any way that suits them. It’s all been easy to set-up and run, the product looks great on site, and the connectivity is super-fast which helps avoid long queues. I’m

RedIRIS taps ADVA and SIA to upgrade national research network21.9.2021 09:00:00 CEST | Press release

ADVA (FSE: ADV) and SIA, Indra’s cybersecurity company, today announced that RedIRIS is deploying ADVA’s technology to create a robust, high-capacity research and education network (NREN). The new long-haul backbone infrastructure connects universities and research facilities across Spain, enabling educators and scientists to share huge data sets and harness bandwidth-intensive applications. Built on the ADVA FSP 3000 and monitored by the ADVA ALM fiber assurance solution, the network carries services at speeds up to 200Gbit/s. Featuring ADVA’s ROADM technology and QuadFlex™ line cards, the open solution has given RedIRIS an easy way to migrate from legacy technology to flexible, high-performance connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005058/en/ ADVA is helping RedIRIS create a long-haul research and education network that stretches throughout Spain (Photo: Business Wire) “Our new transport system

Turquoise Plato Connects to OpenFin to Simplify Complexity on the Buy-Side Trader Desktop21.9.2021 09:00:00 CEST | Press release

OpenFin, the operating system (OS) for enterprise productivity, today announced that LSEG’s (London Stock Exchange Group) Turquoise Plato is connecting to OpenFin in response to the industry need for workflow efficiencies, application interoperability, and a more unified desktop experience for the buy-side and member firm users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005467/en/ Turquoise has a proven track record in delivering innovation and liquidity opportunities to the market, with Turquoise Plato Block Discovery™ having seen record levels of block trading activity on Turquoise® and Turquoise Europe™ in 2020. With this collaboration, Turquoise is continuing to deliver on its mission to identify efficient, collaborative operating models that reduce the implicit cost of trading, contribute to long-term investment returns and drive sustainable growth. Turquoise on OpenFin™ delivers an insightful data feed direc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom